Molnupiravir for the Treatment of COVID-19. Information for Patients
MetadataShow full item record
Other Language Versions
The Pan American Health Organization presents this information sheet with recommendations on the use of molnupiravir addressed to patients. Molnupiravir is a prodrug that significantly inhibits SARS-CoV-2 replication. It is used for the treatment of mild and moderate COVID-19 in patients who are at high risk of complications, and has shown a significant reduction in the rate of hospitalization or death of patients with COVID-19.
This notice should be preserved along with the article's original URL.Attribution-NonCommercial-ShareAlike 3.0 IGO
Showing items related by title, author, creator and subject.
Pan American Health Organization; Health Systems and Services (HSS) (Washington, D.C., PAHO, 2022-07-05)The Pan American Health Organization presents this information sheet with recommendations on the use of molnupiravir addressed to health professionals. Molnupiravir is a prodrug that significantly inhibits SARS-CoV-2 ...
Considerations on the Use of Antivirals, Monoclonal Antibodies, and Other Interventions for the Management of COVID-19 Patients in Latin America and the Caribbean Pan American Health Organization; Evidence and Intelligence for Action in Health (EIH) (Washington, D.C., PAHO, 2022-05-09)Since the onset of the COVID-19 pandemic, a large number of clinical trials have been planned and developed to assess the effectiveness and safety of various interventions that could prevent hospitalizations and progression ...
Regulatory considerations on authorization of the use of convalescent plasma (PC) to address the COVID-19 emergency, 22 April 2020 Pan American Health Organization; Health Emergencies (PHE) (Washington, D.C., PAHO, 2020-04-22)Since the last century, passive immunization has been used for the prevention and treatment of some human infectious diseases. The serum of convalescent patients is the treatment of choice in cases of Argentine Hemorrhagic ...